IT1201087B - Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche - Google Patents

Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche

Info

Publication number
IT1201087B
IT1201087B IT8220781A IT2078182A IT1201087B IT 1201087 B IT1201087 B IT 1201087B IT 8220781 A IT8220781 A IT 8220781A IT 2078182 A IT2078182 A IT 2078182A IT 1201087 B IT1201087 B IT 1201087B
Authority
IT
Italy
Prior art keywords
bipphosphones
procedure
preparation
pharmaceutical compositions
pharmacologically active
Prior art date
Application number
IT8220781A
Other languages
English (en)
Other versions
IT8220781A0 (it
Inventor
Sergio Rosini
Giorgio Staibano
Original Assignee
Gentili Ist Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11171970&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IT1201087(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gentili Ist Spa filed Critical Gentili Ist Spa
Priority to IT8220781A priority Critical patent/IT1201087B/it
Publication of IT8220781A0 publication Critical patent/IT8220781A0/it
Priority to CH1654/83A priority patent/CH661437A5/it
Priority to GB08308791A priority patent/GB2118042B/en
Priority to FR8305858A priority patent/FR2525223B1/fr
Priority to DE19833313049 priority patent/DE3313049A1/de
Priority to DE1996175047 priority patent/DE19675047I2/de
Priority to LU88714C priority patent/LU88714I2/fr
Priority to LU84746A priority patent/LU84746A1/fr
Priority to JP58065160A priority patent/JPS58189193A/ja
Priority to BE2/60071A priority patent/BE896453A/fr
Priority to SE8302130A priority patent/SE463239B/sv
Priority to NL8301324A priority patent/NL192562C/nl
Priority to US06/618,578 priority patent/US4621077A/en
Publication of IT1201087B publication Critical patent/IT1201087B/it
Application granted granted Critical
Priority to HK793/90A priority patent/HK79390A/xx
Priority to MX9203428A priority patent/MX9203428A/es
Priority to NL970038C priority patent/NL970038I2/nl
Priority to NL980004C priority patent/NL980004I1/nl
Priority to NL980005C priority patent/NL980005I1/nl
Priority to NL980010C priority patent/NL980010I1/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3856—Polyphosphonic acids containing halogen or nitro(so) substituents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT8220781A 1982-04-15 1982-04-15 Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche IT1201087B (it)

Priority Applications (19)

Application Number Priority Date Filing Date Title
IT8220781A IT1201087B (it) 1982-04-15 1982-04-15 Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
CH1654/83A CH661437A5 (it) 1982-04-15 1983-03-25 Bifosfonati farmacologicamente attivi, procedimento per la loro preparazione e relative composizioni farmaceutiche.
GB08308791A GB2118042B (en) 1982-04-15 1983-03-30 Pharmaceutical compositions containing biphosphonic acids
FR8305858A FR2525223B1 (fr) 1982-04-15 1983-04-11 Nouveaux acides diphosphoniques, leurs sels, leur procede de preparation et leur application en therapeutique
DE19833313049 DE3313049A1 (de) 1982-04-15 1983-04-12 Pharmakologisch wirksame biphosphonate, verfahren fuer ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen
DE1996175047 DE19675047I2 (de) 1982-04-15 1983-04-12 Pharmazeutische Zusammensetzung mit einem Gehalt an 4-amino-1-hydroxybutan-1, 1-biphosphonsaeure
LU88714C LU88714I2 (fr) 1982-04-15 1983-04-13 Acide 4-amino-1-hydroxybutane-1,1-diphosphonique sels de celui-ci avec un métal alcalin ou une base organique ou un acide aminé basique en particulier le sel trihydraté monosodique de l'acide 4-amino-1-hydroxybutane-1,1-diphosphonique
LU84746A LU84746A1 (fr) 1982-04-15 1983-04-13 Nouveaux acides diphosphoniques,leurs sels,leur procede de preparation et leur application en therapeutique
JP58065160A JPS58189193A (ja) 1982-04-15 1983-04-13 薬理活性を有するバイホスホネートを有効成分とする医薬
BE2/60071A BE896453A (fr) 1982-04-15 1983-04-14 Farmacologisch aktieve bifosfonaten, werkwijze voor hun bereiding en farmaceutica met deze stoffen daarin.
SE8302130A SE463239B (sv) 1982-04-15 1983-04-15 Farmaceutiskt aktiva bifosfonater samt farmaceutiska kompositioner innehaallande desamma
NL8301324A NL192562C (nl) 1982-04-15 1983-04-15 Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
US06/618,578 US4621077A (en) 1982-04-15 1984-06-08 Pharmacologically active biphosphonates, process for the preparation thereof and pharmaceutical compositions therefrom
HK793/90A HK79390A (en) 1982-04-15 1990-10-03 Pharmaceutical compositions containing pharmacologically active biphosphonates
MX9203428A MX9203428A (es) 1982-04-15 1992-06-25 Bifosfonatos activos farmacologicamente, procedimiento para su preparacion y composiciones farmaceuticas de los mismos.
NL970038C NL970038I2 (nl) 1982-04-15 1997-11-07 Farmaceutisch preparaat dat een NH2-(CH2)3-C(P03H2)2OH-verbinding bevat.
NL980004C NL980004I1 (nl) 1982-04-15 1998-01-09 Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
NL980005C NL980005I1 (nl) 1982-04-15 1998-01-26 Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.
NL980010C NL980010I1 (nl) 1982-04-15 1998-03-03 Farmaceutisch preparaat dat een NH2-(CH2)3-C(PO3H2)2OH-verbinding bevat.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT8220781A IT1201087B (it) 1982-04-15 1982-04-15 Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche

Publications (2)

Publication Number Publication Date
IT8220781A0 IT8220781A0 (it) 1982-04-15
IT1201087B true IT1201087B (it) 1989-01-27

Family

ID=11171970

Family Applications (1)

Application Number Title Priority Date Filing Date
IT8220781A IT1201087B (it) 1982-04-15 1982-04-15 Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche

Country Status (12)

Country Link
US (1) US4621077A (it)
JP (1) JPS58189193A (it)
BE (1) BE896453A (it)
CH (1) CH661437A5 (it)
FR (1) FR2525223B1 (it)
GB (1) GB2118042B (it)
HK (1) HK79390A (it)
IT (1) IT1201087B (it)
LU (2) LU88714I2 (it)
MX (1) MX9203428A (it)
NL (5) NL192562C (it)
SE (1) SE463239B (it)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8419489D0 (en) * 1984-07-31 1984-09-05 Leo Pharm Prod Ltd Chemical compounds
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
DE3512536A1 (de) * 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3540150A1 (de) * 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4963681A (en) * 1987-07-06 1990-10-16 Norwich Eaton Pharmaceuticals, Inc. Process for synthesis of aminomethylene phosphonoalkylphosphinates
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5227506A (en) * 1989-09-06 1993-07-13 Merck & Co., Inc. Acyloxymethyl esters of bisphosphonic acids as bone resorption inhibitors
FI83657C (fi) * 1989-09-08 1991-08-12 Huhtamaeki Oy Foerfarande foer framstaellning av metylenbisfosfonsyror.
US5356887A (en) * 1990-01-31 1994-10-18 Merck & Co., Inc. Pharmaceutical compositions containing insoluble calcium salts of amino-hydroxybutylidene bisphoshonic acids
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
GB2248061A (en) * 1990-09-18 1992-03-25 Merck & Co Inc Amino-hydroxy-alkylidene bis phosphonic acids
US5183815A (en) * 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
IT1247034B (it) * 1991-06-26 1994-12-12 Gentili Ist Spa Acidi dimetilamino-idrossi alchil difosfonici e loro sali, loro procedimento produttivo e composizioni farmaceutiche che li comprendono
US6096342A (en) * 1997-03-12 2000-08-01 The Procter & Gamble Company Dosage forms of risedronate
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
TW237386B (it) * 1992-04-15 1995-01-01 Ciba Geigy
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6399592B1 (en) 1992-12-23 2002-06-04 Merck & Co., Inc. Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5591730A (en) * 1993-10-12 1997-01-07 The Regents Of The University Of California Inhibition of urinary calculi growth
US5854227A (en) * 1994-03-04 1998-12-29 Hartmann; John F. Therapeutic derivatives of diphosphonates
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5449819A (en) * 1994-06-06 1995-09-12 Merck & Co., Inc. Process for removing waste pox, alendronate and its by products
US6008206A (en) * 1994-09-21 1999-12-28 Merck & Co., Inc. Sodium alendronate preparation for local administration
JP3411690B2 (ja) * 1994-09-21 2003-06-03 帝人株式会社 局所投与用アレンドロン酸ナトリウム製剤
KR19980702210A (ko) * 1995-02-17 1998-07-15 폴락 돈나 엘 비척추골 골절의 위험률을 감소시키는 방법
US20010051616A1 (en) * 1995-02-17 2001-12-13 David B. Karpf Method of lessening the risk of vertebral fractures
WO1996035407A1 (en) * 1995-05-12 1996-11-14 Merck & Co., Inc. Prevention of tooth loss by the administration of alendronate or its salts
AU5973496A (en) 1995-06-06 1996-12-24 Merck & Co., Inc. Bisphosphonate cement composition to prevent aseptic loosening of orthopedic implant devices
EP0837863A4 (en) * 1995-06-06 1999-06-16 Merck & Co Inc DISODIUM ALENDRONATE PREPARATIONS
JP3344726B2 (ja) * 1995-06-06 2002-11-18 メルク エンド カンパニー インコーポレーテッド 無水アレンドロネート一ナトリウム塩製剤
EP1820497A3 (en) * 1996-05-17 2009-07-22 Merck & Co., Inc. Effervescent bisphosphonate formulation
JP2000511178A (ja) * 1996-05-17 2000-08-29 メルク エンド カンパニー インコーポレーテッド 発泡性ビスホスホネート製剤
EP1378234A1 (en) * 1996-05-17 2004-01-07 MERCK & CO. INC. Effervescent bisphosphonate formulation
PL332496A1 (en) * 1996-10-04 1999-09-13 Merck & Co Inc Liquid alendronate preparations
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
US6410782B1 (en) 1997-07-09 2002-06-25 Geange Ltd. Diphosphonic acid salts for the treatment of osteoporosis
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6416964B2 (en) 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
US8586781B2 (en) * 1998-04-02 2013-11-19 Mbc Pharma, Inc. Bone targeted therapeutics and methods of making and using the same
US6214812B1 (en) * 1998-04-02 2001-04-10 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US6750340B2 (en) 1998-04-02 2004-06-15 Mbc Research, Inc. Bisphosphonate conjugates and methods of making and using the same
US7598246B2 (en) * 1998-04-02 2009-10-06 Mbc Pharma, Inc. Bisphosphonate conjugates and methods of making and using the same
US6896871B2 (en) 1998-04-02 2005-05-24 Mbc Research, Inc. Biphosphonate conjugates and methods of making and using the same
US20030078211A1 (en) * 1998-06-24 2003-04-24 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
AU757104B2 (en) 1998-06-24 2003-01-30 Merck & Co., Inc. Compositions and methods for inhibiting bone resorption
US6008207A (en) * 1998-08-13 1999-12-28 Merck & Co., Inc. Anhydrous alendronate monosodium salt formulations
CA2341459A1 (en) * 1998-08-27 2000-03-09 Nina Finkelstein Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
US6331533B1 (en) 1998-11-16 2001-12-18 Merck & Co., Inc. Method for inhibiting dental resorptive lesions
BR0010112A (pt) * 1999-02-17 2001-12-26 Teva Pharma Processo para preparação de ácido alendrÈnico
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
SE9903345D0 (sv) * 1999-09-17 1999-09-17 Astra Pharma Prod Novel process
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
AR021347A1 (es) * 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
US6677320B2 (en) 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance
US6562974B2 (en) 2000-02-01 2003-05-13 The Procter & Gamble Company Process for making geminal bisphosphonates
US6410520B2 (en) 2000-02-01 2002-06-25 The Procter & Gamble Company Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate
US6468559B1 (en) 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US6476006B2 (en) 2000-06-23 2002-11-05 Teva Pharmaceutical Industries, Ltd. Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
US20040038946A1 (en) * 2001-04-27 2004-02-26 Wilson Lon J. Fullerene-based drugs targeted to bone
BR0209360A (pt) * 2001-05-02 2004-06-08 Novartis Ag Método de administração de bisfosfonatos por inalação no tratamento ou prevenção de reabsorção óssea e osteoporose
US20030216358A1 (en) * 2001-07-05 2003-11-20 Muchmore Douglas Boyer Method for enhancing bone mineral density gain
CN100479823C (zh) * 2001-12-21 2009-04-22 宝洁公司 双膦酸盐在制造药物套盒中的用途以及用于增加骨质的套盒
US20050070504A1 (en) * 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US7488496B2 (en) * 2002-03-06 2009-02-10 Christer Rosen Effervescent compositions comprising bisphosphonates and methods related thereto
US20050176685A1 (en) * 2002-04-05 2005-08-11 Daifotis Anastasia G. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
ITMI20020908A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione di sodio alendronato
KR20090106663A (ko) 2002-05-10 2009-10-09 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
AU2003233569A1 (en) * 2002-05-17 2003-12-02 Teva Pharmaceutical Industries Ltd. Use of certain diluents for making bisphosphonic acids
US20040137058A1 (en) * 2002-07-09 2004-07-15 Katdare Ashok V. Effervescent bisphosphonate formulation
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
CN1649598B (zh) * 2002-12-20 2011-12-07 弗·哈夫曼-拉罗切有限公司 高剂量伊班膦酸制剂
US20040206932A1 (en) 2002-12-30 2004-10-21 Abuelyaman Ahmed S. Compositions including polymerizable bisphosphonic acids and methods
CN1325506C (zh) * 2003-05-15 2007-07-11 中国科学院上海药物研究所 骨重吸收抑制剂阿伦膦酸及生理可接受的盐和它的制备
US7452924B2 (en) * 2003-08-12 2008-11-18 3M Espe Ag Self-etching emulsion dental compositions and methods
WO2005027921A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
US20050181043A1 (en) * 2004-02-12 2005-08-18 Indranil Nandi Alendronate salt tablet compositions
US20050261250A1 (en) * 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
RS51562B (en) 2004-05-24 2011-08-31 Warner Chilcott Company Llc. ENTERICAL SOLID ORAL DOSAGE FOR BISPHOSPHONATES CONTAINING HELAT
KR100564628B1 (ko) * 2004-06-16 2006-03-28 삼성전자주식회사 스플릿 게이트형 플래쉬 메모리 소자 및 그 제조방법
JP5214242B2 (ja) 2004-07-08 2013-06-19 スリーエム イノベイティブ プロパティズ カンパニー 歯科用の方法、組成物、および酸感受性色素を含むキット
ATE526006T1 (de) 2004-08-11 2011-10-15 3M Innovative Properties Co Selbstklebende zusammensetzungen mit einer vielzahl von sauren verbindungen
US8012949B2 (en) * 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
CN1304401C (zh) * 2004-12-28 2007-03-14 浙江工业大学 一种阿伦膦酸的制备方法
NZ561666A (en) * 2005-03-17 2010-05-28 Elan Pharma Int Ltd Nanoparticulate biphosphonate compositions
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
US20070087052A1 (en) * 2005-10-19 2007-04-19 Katdare Ashok V Effervescent bisphosphonate formulation
DE112007000280A5 (de) 2006-02-03 2008-10-30 HÄRING, Thomas Phosphonsäure-haltige Blends und Phosphonsäure-haltige Polymere
JP2009530414A (ja) * 2006-03-17 2009-08-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ ビスホスホネート化合物及び方法
ZA200900603B (en) * 2006-11-21 2010-05-26 Teikoku Pharma Usa Inc Biphosphonate inhalant formulations and methods for using the same
JP5507256B2 (ja) 2006-12-13 2014-05-28 スリーエム イノベイティブ プロパティズ カンパニー 酸性成分及び光退色性染料を有する歯科用組成物の使用方法
US20080182823A1 (en) * 2007-01-26 2008-07-31 Hidesmasa Katsumi Polymer-linked-biophosphonate inhalant formulations and methods for using the same
EP2543368A1 (en) 2007-12-11 2013-01-09 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
CN101932306A (zh) * 2008-02-05 2010-12-29 阿特维斯集团公司 阿仑膦酸盐制剂、其制备方法和使用方法
US7964584B2 (en) * 2008-08-01 2011-06-21 Dong Wha Pharmaceutical Co., Ltd. Method of treating or preventing osteoporosis comprising administering to a patient in need thereof an effective amount of pharmaceutical composition comprising benzamidine derivatives or their salts, and alendronic acid or its salt
US20100034752A1 (en) * 2008-08-11 2010-02-11 Toru Hibi Inhalant formulations comprising a bisphosphonate and a pyrazolone derivative and methods for using the same
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
US9334300B2 (en) 2011-08-01 2016-05-10 Mbc Pharma, Inc. Vitamin B6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
CN114404427A (zh) 2014-02-13 2022-04-29 配体药物公司 前药化合物及其用途
PL407922A1 (pl) 2014-04-16 2015-10-26 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Nowe bisfosfoniany i ich zastosowanie
US9994600B2 (en) 2014-07-02 2018-06-12 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
AU2019207625A1 (en) 2018-01-09 2020-07-30 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143123A (en) * 1966-05-18 1969-02-19 Albright & Wilson Mfg Ltd Phosphate compositions
GB1235029A (en) * 1966-12-29 1971-06-09 Procter & Gamble Stannous polyphosphonates and their use in oral compositions for caries prophylaxis
PH9776A (en) * 1967-12-11 1976-03-17 M Francis Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue and method of use
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
PH9853A (en) * 1972-06-08 1976-04-13 M Francis Compositions for inhibiting mobilization of calcium phosphate in animal tissue and method of use thereof
IE37842B1 (en) * 1972-06-30 1977-10-26 Procter & Gamble Oral compositions for plaque caries and calculus retardation with reduced staining tendencies
IE39282B1 (en) * 1973-05-23 1978-09-13 Procter & Gamble Radionuclide labelled phosphonic acids for the treatment of calcific tumors
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US3987157A (en) * 1974-08-29 1976-10-19 Union Carbide Corporation Technetium 99-m labeled radio-diagnostic agents employing stannous tartrate and method of preparation
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
JPS5283957A (en) * 1975-12-01 1977-07-13 Henkel & Cie Gmbh Medicine for treating metabolic obstruction of calcium
US4137309A (en) * 1976-10-14 1979-01-30 The Procter & Gamble Company Therapeutic treatment
US4275059A (en) * 1977-03-28 1981-06-23 The Procter & Gamble Company Salicylate anti-inflammatory composition
US4216211A (en) * 1977-10-31 1980-08-05 The Procter & Gamble Company Therapeutic composition
US4330537A (en) * 1977-12-07 1982-05-18 The Procter & Gamble Company Compositions for inhibiting mobilization of calcium phosphate in animal tissue
US4230700A (en) * 1977-12-07 1980-10-28 The Procter & Gamble Company Methods for inhibiting mobilization of calcium phosphate in animal tissue
US4216212A (en) * 1978-06-08 1980-08-05 The Procter & Gamble Company Pyrazolidine anti-inflammatory composition and methods of use
IT1097292B (it) * 1978-06-27 1985-08-31 Gentili Ist Spa Composizione farmaceutica per la terapia dell'ittero ostruttivo non neoplastico
US4282214A (en) * 1978-07-31 1981-08-04 The Procter & Gamble Company Phenylacetate anti-inflammatory composition
US4264582A (en) * 1978-07-31 1981-04-28 The Procter & Gamble Company Isobutylphenylacetate anti-inflammatory composition
US4254114A (en) * 1979-01-02 1981-03-03 The Proctor & Gamble Company Control of pyrophosphate microorganisms with organophosphonates
GB2043072B (en) * 1979-02-13 1983-11-23 Symphar Sa Diphosphonate compounds
GB2076889B (en) * 1980-03-12 1983-10-26 Cadbury Schweppes Transport Feeding fuel and water emulsion i c engines
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
GB2079285B (en) * 1980-07-09 1984-05-23 Symphar Sa Dipthosphonate derivatives and pahrmaceutical compositions containing them
GB2082585A (en) * 1980-08-27 1982-03-10 Vysoka Skola Chem Tech 6-amino-1-hydroxyhexylidene diphosphonic acid, salts thereof and a method of producing the acid and salts.
JPS5759900A (en) * 1980-09-29 1982-04-10 Vysoka Skola Chem Tech 6-amino-1-hydroxyhexylidene diphosphonic acid
BE890453A (fr) * 1980-10-07 1982-03-22 Procter & Gamble Procede d'inhibition des metastases de cellules tumorales
US4330530A (en) * 1980-12-22 1982-05-18 The Procter & Gamble Company Anti-arthritic compositions and method using gold salts and organophosphonates
IT1194748B (it) * 1981-02-12 1988-09-28 Gentili Ist Spa Composizioni farmaceutiche per il trattamento di osteopatie

Also Published As

Publication number Publication date
JPH0213645B2 (it) 1990-04-04
FR2525223A1 (fr) 1983-10-21
HK79390A (en) 1990-10-12
CH661437A5 (it) 1987-07-31
JPS58189193A (ja) 1983-11-04
SE463239B (sv) 1990-10-29
SE8302130D0 (sv) 1983-04-15
NL192562C (nl) 1997-10-03
NL970038I1 (nl) 1998-01-05
MX9203428A (es) 1992-07-01
NL980004I1 (nl) 1998-04-01
GB8308791D0 (en) 1983-05-11
IT8220781A0 (it) 1982-04-15
LU84746A1 (fr) 1983-11-17
GB2118042A (en) 1983-10-26
BE896453A (fr) 1983-08-01
NL192562B (nl) 1997-06-02
US4621077A (en) 1986-11-04
NL980010I1 (nl) 1998-05-06
GB2118042B (en) 1986-01-15
NL980005I1 (nl) 1998-04-01
LU88714I2 (fr) 1996-08-23
SE8302130L (sv) 1983-10-16
NL8301324A (nl) 1983-11-01
FR2525223B1 (fr) 1986-04-25
NL970038I2 (nl) 2000-11-01

Similar Documents

Publication Publication Date Title
IT1201087B (it) Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
IT8722790A0 (it) Composti farmacologicamente attivi, procedimenti per la loro preparazione e composizioni che li contengono.
IT8767057A0 (it) Composizioni farmaceutiche a cessione prolungata relative forme di dosaggio e procedimento per la loro preparazione
IT8347605A0 (it) Uree e tiouree sostituite aventi attivita' antiaterosclerotica, procedimento per la loro preparazione e composizioni farmaceutiche che le contengono
IT1200944B (it) Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico
IT8219486A0 (it) Nuovi composti ad attivita'antiinfiammatoria, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT8320468A0 (it) Nuovi composti ad attivita'antiinfiammatoria, procedimento per la loro preparazione e composizioni farmaceutiche che licontengono.
IT8221678A0 (it) Esteri basici ad attivita'calcioantagonista, procedimenti per la loro preparazione e relative composizioni farmaceutiche.
IT8448800A0 (it) Amminociclopentani, composizioni farmaceutiche che li contengono eprocedimento per la loro preparazione
IT1167746B (it) Nitroimidazoli ad attivita' tricomonacida, procedimento per la loro preparazione e relative composizioni farmaceutiche
IT8621135A0 (it) Derivati dell'acito cef-3-em-4-carbossilico, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
IT8348518A0 (it) Piperidinoguanidine sostituite,procedimento per la loro preparazione e composizioni farmaceutiche che le contengono
IT8747852A0 (it) Benzammidi sostituite, procedimento per la loro preparazione e composizioni farmaceutiche che le contengono
IT8223220A0 (it) Aril-alchil-piperazine farmaceuticamente attive, procedimenti per la loro preparazione e composizioni relative.
IT8622783A0 (it) Derivati imidazolici adattivita' terapeutica, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
IT8322854A0 (it) Aril-alchil-piperazine farmaceuticamente attive, procedimenti per la loro preparazione e composizioni relative.
IT8124419A0 (it) Composti farmaceuticamente attivi, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
IT1218324B (it) Composti ad attivita' calcio-antagonista,metodo per la loro preparazione e composizioni farmaceutiche
IT1198378B (it) Composti idrossiminici e alcossiminici ad attivita' calcioanatagonista,procedimento per la loro preparazione e relative composizioni farmaceutiche
IT8422633A0 (it) Aril-alchil-piperazine farmaceuticamente attive, procedimenti per la loro preparazione e composizioni relative.
IT8222842A0 (it) Nuovi composti antiinfiammatori ed analesici, procedimento per la loro preparazione e relative composizioni farmaceutiche.
IT8124004A0 (it) Farmaceuticamente attive, aril-alchil-piperazine procedimenti per la loro preparazione e composizioni relative.
IT8024812A0 (it) Aril-alchil-piperazine farmaceuticamente attive, procedimenti per la loro preparazione e composizioni relative.
IT1157908B (it) Nuovo composto farmacologicamente attivo, procedimento per la sua preparazione e relative composizioni farmaceutiche
IT1217192B (it) Tioeteri chinolinici,procedimento per la loro preparazione e composizioni farmaceutiche che li contengono

Legal Events

Date Code Title Description
ITCP Complementary protection certificate

Free format text: CCP 481

MEDD Supplementary protection certificate for pharmaceutical products: granted

Free format text: CCP 481, 19931022; ISTITUTO GENTILI S.P.A.

TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970329